Ferritin as a Platform for Creating Antiviral Mosaic Nanocages: Prospects for Treating COVID-19

Kourosh H. Ebrahimi*

*Corresponding author for this work

Research output: Contribution to journalComment/debatepeer-review

1 Citation (Scopus)


Infectious diseases are a continues threat to human health and the economy worldwide. The latest example is the global pandemic of COVID-19 caused by SARS-CoV-2. Antibody therapy and vaccines are promising approaches to treat the disease; however, they have bottlenecks: they might have low efficacy or narrow breadth due to the continuous emergence of new strains of the virus or antibodies could cause antibody-dependent enhancement (ADE) of infection. To address these bottlenecks, I propose the use of 24-meric ferritin for the synthesis of mosaic nanocages to deliver a cocktail of antibodies or nanobodies alone or in combination with another therapeutic, like a nucleotide analogue, to mimic the viral entry process and deceive the virus, or to develop mosaic vaccines. I argue that available data showing the effectiveness of ferritin-antibody conjugates in targeting specific cells and ferritin-haemagglutinin nanocages in developing influenza vaccines strongly support my proposals.

Original languageEnglish
Pages (from-to)1371-1378
Number of pages8
JournalChembiochem : a European journal of chemical biology
Issue number8
Publication statusPublished - 16 Apr 2021


  • Angiotensin-Converting Enzyme 2/chemistry
  • Animals
  • Antibodies/chemistry
  • Antiviral Agents/chemistry
  • COVID-19/drug therapy
  • COVID-19 Vaccines/chemistry
  • Drug Carriers/chemistry
  • Ferritins/chemistry
  • Humans
  • Mice
  • Nanostructures/chemistry
  • SARS-CoV-2/isolation & purification
  • Serine Endopeptidases/chemistry
  • Virus Internalization/drug effects


Dive into the research topics of 'Ferritin as a Platform for Creating Antiviral Mosaic Nanocages: Prospects for Treating COVID-19'. Together they form a unique fingerprint.

Cite this